|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
DALLAS, April 05, 2018-- Nexeon MedSystems Inc a neurostimulation medical device company, announced today financial results for the fourth quarter and full year ended December 31, 2017.. Manufacturing ...
NEW YORK, NY / ACCESSWIRE / December 21, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has ...
Company to Host Conference Call November 20, 2017 4pm CST DALLAS , Nov. 20, 2017 /PRNewswire/ -- Nexeon MedSystems Inc. (OTCQB: NXNN, "Nexeon", "the Company"), is providing shareholders ...
"I'm proud of our management team for implementing and delivering on innovative financing strategies in much the same fashion as our engineers do," said Nexeon CEO Will Rosellini. In June 2017, the Securities and Exchange Committee (SEC) declared effective the Company's S-1 Registration Statement. The S-1 registered 5,332,496 shares of the Company's common stock.
LIEGE, Belgium, Sept. 6, 2017 /PRNewswire/ -- Nexeon MedSystems ("Nexeon" or "the Company") (NXNN) announced today that it has exercised its option to acquire Nexeon Medsystems Belgium, SPRL ("NMB"). This Belgian-based company has been operating since 2013 developing neurostimulation products. NMB recently acquired Medi-Line, a Belgian medical device manufacturer with financing support provided by KBC and CBC Bank. Medi-Line has expertise in active and non-active implants, and it has been profitable for its complete 25-year corporate history. For more information about the transaction, please review the Form 8-K.